Facebook Linkedin Soundcloud Twitter Vimeo Xing
Home Tags BCMA-targeted therapies

Tag: BCMA-targeted therapies

ASCO 2022: Belantamab Mafodotin in the Treatment of Patients with Relapsed/Refractory...

ADC Review | Editorial Team
The treatment patients diagnosed with relapsed or relapsed/refractory multiple myeloma (RRMM), those who have relapsed or who are refractory to at least 1 line of...

DREAMM-2 Trial Shows Positive Results for Belantamab Mafodotin in Multiple Myeloma

Peter Hofland
Earlier today positive headline results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916), an anti-BCMA antibody-drug conjugate or...
Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

SpringWorks and GlaxoSmithKline to Collaborate in the Development of Belantamab Mafodotin

Peter Hofland
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, and GlaxoSmothKline have entered into...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X